Climb Bio, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
CLYM$11.74+6.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(13,722) | $(20,781) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 1,605 | 2,022 |
| Non-cash operating lease expense | 58 | 39 |
| Accretion of discounts on marketable securities, net | (305) | (669) |
| Depreciation and amortization expense | 38 | — |
| Unrealized foreign currency transaction loss | 21 | 24 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 929 | 1,893 |
| Other long-term assets | — | (10) |
| Accounts payable | (1,409) | 72 |
| Accrued expenses and other current liabilities | (1,532) | 2,035 |
| Operating lease liabilities | (62) | (59) |
| Net cash used in operating activities | (14,379) | (15,434) |
| Cash flows from investing activities: | ||
| Purchases of marketable securities | (44,855) | (58,751) |
| Proceeds from maturities of marketable securities | 31,900 | 16,000 |
| Net cash used in investing activities | (12,955) | (42,751) |
| Cash flows from financing activities: | ||
| Proceeds from exercise of stock options | 5 | — |
| Net cash provided by financing activities | 5 | — |
| Effect of exchange rate changes on cash and cash equivalents | — | (24) |
| Net change in cash and cash equivalents | (27,329) | (58,209) |
| Cash and cash equivalents at beginning of period | 35,685 | 87,229 |
| Cash and cash equivalents at end of period | $8,356 | $29,020 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for leases included in operating cash outflows | $73 | $69 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.